Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vioxx Litigation May Freeze Class-Wide Drug Development, AEI Scholar Calfee Suggests

This article was originally published in The Pink Sheet Daily

Executive Summary

Former FDA Chief Counsel Troy says Merck’s strategy to defend each case independently may backfire.

You may also be interested in...



Increased Safety Concerns Could Reduce Drug Development Pipelines By 20%, IMS Says

The pharmaceutical research firm cites increased regulatory scrutiny and post-marketing commitments as catalyst.

Increased Safety Concerns Could Reduce Drug Development Pipelines By 20%, IMS Says

The pharmaceutical research firm cites increased regulatory scrutiny and post-marketing commitments as catalyst.

Merck's Appeal In Vioxx Case Likely To Focus On Expert Testimony, Evidentiary Rulings

In the first Vioxx product liability case to reach trial, a Texas jury awards the plaintiff $253.5 mil. in damages, the bulk of which are punitive damages that would be capped under state law.

Related Content

Topics

UsernamePublicRestriction

Register

PS062997

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel